SAMWHA ELECTRIC, a Leading Manufacturer of Electrolytic Capacitor, Draws Attention in World Electronics Market
24.4.2020 11:00:00 EEST | Business Wire | Press release
SAMWHA ELECTRIC (KRX:009470), a specialty manufacturer of electrolytic capacitors in Korea, attracts attention in the world electronics market by launching a conductive polymer hybrid electrolytic capacitor built on advanced technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200424005097/en/
SAMWHA ELECTRIC, a specialty manufacturer of electrolytic capacitors in Korea, attracts attention in the world electronics market by launching a conductive polymer hybrid electrolytic capacitor built on advanced technology. SAMWHA ELECTRIC has been providing the global market with its electric double layer capacitor ‘Green-Cap’ used for eco-friendly high-valued products, such as 5G, eco-friendly vehicles, medical devices, LED, robots, Internet-of-Things (IoT), and energy storage systems (ESSs) for wind and solar power for many years. Thanks to a long replacement cycle based on fast charge/discharge cycles for over 1 million times, Green-Cap is easy to maintain and it can be used in extreme temperatures. As it does not contain environmentally hazardous substances, it is also easy to treat after use. (Graphic: Business Wire)
SAMWHA ELECTRIC has been providing the global market with its electric double layer capacitor ‘Green-Cap’ used for eco-friendly high-valued products, such as 5G, eco-friendly vehicles, medical devices, LED, robots, Internet-of-Things (IoT), and energy storage systems (ESSs) for wind and solar power for many years.
Thanks to a long replacement cycle based on fast charge/discharge cycles for over 1 million times, Green-Cap is easy to maintain and it can be used in extreme temperatures. As it does not contain environmentally hazardous substances, it is also easy to treat after use.
With increasing demand in strategic markets including electric vehicles, communication, smart consumer electronics, renewable energies, UPS, automotive industry and electronic components, orders for the product is growing worldwide. Through its five sales subsidiaries in Germany, the United States, China, Thailand and India as well as 14 major regional offices in other countries, the company has built stable international business infrastructure to lead the global market.
Expecting brighter future in line with expansion in eco-friendly automotive infrastructure and increase in demand for eco-friendly power due to expanded environment regulation policies, SAMWHA ELECTRIC aims to meet demands for high-specification products by developing high-valued devices at its corporate R&D center and to take an advantageous position while transforming into a leading electronic component company by developing proprietary technologies.
“In order to grow into an integrated electronic parts maker through systematic quality control, we are implementing management systems in three stages, and effectively managing production processes with enterprise resource planning (ERP), a real-time data management system, and manufacturing execution system (MES),” said a manager at SAMWHA ELECTRIC.
Backed by these efforts, SAMWHA ELECTRIC is further advancing into the global market with synergies of designation as one of beneficiaries of support program of the Korea Trade-Investment Promotion Agency (KOTRA). The company also values shared growth with affiliates by establishing partnership relations. The corporate culture of SAMWHA ELECTRIC that shares values with clients has potential for further development with their trust.
Products by SAMWHA ELECTRIC
- EDLC (Electric Double Layer Capacitor) for Radial, Snap-in, Axial Type & Module
- Conductive Polymer Hybrid Aluminum Electrolytic Capacitor for Radial, SMD Type
- Aluminum Electrolytic Capacitor for Radial, SMD, Snap-in, Lug, Screw Type
Main Application
- Household Appliance for High Ripple Current, Miniaturization and Long Life
- Solar Power Inverter for High Voltage, High Capacitance and High Ripple Current
- Power Electronics for High Capacitance, High Ripple Current and Long Life and Power Industry, Plant Business, Infrastructure Business Segment
- Led Lighting for Ultra-High Temperature, Long Life and Low Impedance
- Automotive for powertrain (ECU, DC/DC Converter), Safety (Breaking, Airbag, ABS) and Exterior (LED Headlight)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200424005097/en/
Contact information
SAMWHA Electric H.Q.
Mr. Yong Dong Kim
+82-2-2056-1646
sesale1@samwha.com
SAMWHA EUROPE GmbH
Mr. Kwang Hyun Park
+49-0-69-9637-65-0
europe@samwha.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom